<DOC>
	<DOCNO>NCT00312429</DOCNO>
	<brief_summary>Umbilical cord blood important source stem cell use treat blood immune system disorder certain type cancer . Stem cell transplant umbilical cord blood show effective treating illness child , research need confirm benefit procedure adult . The purpose study examine immune system response cord blood stem cell transplantation adult advance blood disorder cancer .</brief_summary>
	<brief_title>Umbilical Cord Blood Stem Cell Transplantation Adults With Advanced Blood Disorders Cancer</brief_title>
	<detailed_description>The use umbilical cord blood stem cell treat blood disorder cancer important medical advance ; currently , 45 disorder treat method . While bone marrow transplant common method stem cell donation , research show many advantage use allogeneic graft stem cell obtain umbilical cord blood . Cord blood stem cell relatively easy obtain . Additionally , perfect donor match necessary , thereby decrease likelihood graft-versus-host disease ( GVHD ) , serious side effect donor stem cell attack recipient 's tissue . Cord blood use successfully pediatric patient benefit adult remain untested . The purpose study evaluate effectiveness umbilical cord blood stem cell transplantation adult advance blood disorder cancer . Upon receive allogeneic stem cell transplant use umbilical cord blood , participant observe successful engraftment transplant stem cell `` take '' begin produce new blood cell . The incidence GVHD overall immune system 's response also examine . In turn , finding may guide future umbilical cord blood stem cell clinical trial . This 1-year study enroll individual advance blood disease cancer . Participants receive allogeneic umbilical cord blood stem cell transplant closely monitor hospital determine engraftment occur GVHD develops . Study visit occur Months 1 , 2 , 3 , 6 , 9 , Year 1 . At visit , participant blood drawn laboratory test evaluation immune system response . Quality life questionnaire also complete visit .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Diagnosis review transplant center confirm fit criterion high risk blood disease cancer , define study Estimated life expectancy least 6 week follow study entry Cancer Leukemia Group B ( CALGB ) performance status less equal 2 White blood cell count , platelet , hematocrit , tuberculosis , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , creatinine , HIV test result review transplant center Multiple gate acquisition ( MUGA ) , echocardiogram , cardiac MRI , and/or pulmonary function test ( PFT ) perform review transplant center ( individual ejection fraction diffuse capacity [ DLCO ] 4050 % , appropriate cardiology pulmonary consultation consider individual severe heart lung disease initiation therapy ) Sufficient number umbilical cord blood unit available transplantation If female , willing use contraception throughout study Undergoing Interleukin2 ( IL2 ) therapy within 8 week study entry Diagnosed medical psychiatric illness may interfere study participation Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>